CL2022000156A1 - Degradador selectivo del receptor de estrógeno - Google Patents

Degradador selectivo del receptor de estrógeno

Info

Publication number
CL2022000156A1
CL2022000156A1 CL2022000156A CL2022000156A CL2022000156A1 CL 2022000156 A1 CL2022000156 A1 CL 2022000156A1 CL 2022000156 A CL2022000156 A CL 2022000156A CL 2022000156 A CL2022000156 A CL 2022000156A CL 2022000156 A1 CL2022000156 A1 CL 2022000156A1
Authority
CL
Chile
Prior art keywords
estrogen receptor
selective estrogen
receptor degrader
chromen
azetidin
Prior art date
Application number
CL2022000156A
Other languages
English (en)
Inventor
Trinadha Rao Chitturi
Ranjan Kumar Pal
Biswajit Samanta
Jayraj Dilipbhai Aradhye
Sandeep Pankajkumar Pathak
Kaushik Dhanjibhai Prajapati
Bhavesh Mohanbhai Panchal
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of CL2022000156A1 publication Critical patent/CL2022000156A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un degradador selectivo del receptor de estrógeno (SERD), un compuesto 3-(3,5-difluorofenil)-2-[4-[(E)-3-[3-(fluorometil)azetidin-1-il]prop-1-enil]fenil]-4-metil-2H-cromen-7-ol y su enantiómero S, (2S)-3-(3,5-difluorofenil)-2-[4-[(E)-3-[3-(fluorometil)azetidin-1-il]prop-1-enil]fenil]-4-metil-2H-cromen-7-ol, o sales farmacéuticamente aceptables de estos. También se proporcionan procesos para su preparación. También se proporciona el uso de estos compuestos para el tratamiento de enfermedades relacionadas con la modulación de los receptores de estrógeno, tales como el cáncer de mama positivo para ER.
CL2022000156A 2019-07-22 2022-01-22 Degradador selectivo del receptor de estrógeno CL2022000156A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201921029554 2019-07-22

Publications (1)

Publication Number Publication Date
CL2022000156A1 true CL2022000156A1 (es) 2022-11-18

Family

ID=71842730

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000156A CL2022000156A1 (es) 2019-07-22 2022-01-22 Degradador selectivo del receptor de estrógeno

Country Status (14)

Country Link
US (2) US11014915B2 (es)
EP (1) EP4003525A1 (es)
JP (1) JP2022541938A (es)
KR (1) KR20220046586A (es)
CN (1) CN114302879A (es)
AU (1) AU2020317099A1 (es)
BR (1) BR112022001285A2 (es)
CA (1) CA3148592A1 (es)
CL (1) CL2022000156A1 (es)
IL (1) IL290036A (es)
MX (1) MX2022001013A (es)
PE (1) PE20221588A1 (es)
WO (1) WO2021014386A1 (es)
ZA (1) ZA202201157B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3148592A1 (en) * 2019-07-22 2021-01-28 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
WO2023150056A1 (en) * 2022-02-01 2023-08-10 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
EP0470310B1 (en) 1990-08-09 1995-11-29 Council of Scientific and Industrial Research Novel benzopyrans and process for their production
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
WO1999002512A1 (en) 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
ES2627692T3 (es) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
CA2857061A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
MX2015017655A (es) 2013-06-19 2016-04-15 Seragon Pharmaceuticals Inc Modulador de receptores de estrogeno y uso del mismo.
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
CN103879283B (zh) * 2014-03-10 2019-01-15 浙江吉利汽车研究院有限公司 一种电动车辆
JP2017538727A (ja) * 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療に有用な２，３−ジフェニルクロメンの誘導体
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
RS63217B1 (sr) * 2015-10-27 2022-06-30 Sun Pharma Advanced Res Co Ltd Novi heterociklični antiestrogeni
CA3148592A1 (en) * 2019-07-22 2021-01-28 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader

Also Published As

Publication number Publication date
US11014915B2 (en) 2021-05-25
CA3148592A1 (en) 2021-01-28
BR112022001285A2 (pt) 2022-03-22
CN114302879A (zh) 2022-04-08
IL290036A (en) 2022-03-01
AU2020317099A1 (en) 2022-02-24
WO2021014386A1 (en) 2021-01-28
KR20220046586A (ko) 2022-04-14
ZA202201157B (en) 2023-07-26
JP2022541938A (ja) 2022-09-28
EP4003525A1 (en) 2022-06-01
US20210024504A1 (en) 2021-01-28
US20210261534A1 (en) 2021-08-26
PE20221588A1 (es) 2022-10-10
MX2022001013A (es) 2022-02-22

Similar Documents

Publication Publication Date Title
CL2022000156A1 (es) Degradador selectivo del receptor de estrógeno
DOP2021000070A (es) Inhibidores de la proteína tirosina fosfatasa
EA201791002A1 (ru) Новые соединения, модулирующие fxr (nr1h4)
UY38767A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
UY32352A (es) Régimen de dosificación para un agonista de los receptores de s1p
EA201000046A1 (ru) Замещенные имидазогетероциклы
EA201690328A1 (ru) Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
UY32996A (es) Antagonistas del receptor crth2 basados en indol
UY30292A1 (es) Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor b(beta)2 adrenérgico
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
WO2020081410A3 (en) Radioligands for imaging the lpa1 receptor
CR11098A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
UY33118A (es) Indazoles aminotiazolona sustituidos como moduladores del receptor a relacionado con estrógenos
MX2023000787A (es) Compuestos de indol como moduladores de los receptores de andrógeno.
ZA202100593B (en) Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
AU2017268006A8 (en) Benzenesulfonamide compounds and their use as therapeutic agents
CO2019008941A2 (es) Moduladores del receptor de estrógeno
CO2022006466A2 (es) Inhibidores de egfr alostéricos y métodos de uso de los mismos
UY33722A (es) Oxazolidinonas como moduladores de mglur5
NZ766972A (en) Compounds having s1p5 receptor agonistic activity
MX2021007687A (es) Sales novedosas de degradadores selectivos de receptores de estrogeno.
WO2019123482A8 (en) Pharmaceutical composition for the treatment of cancer
ECSP088878A (es) Proceso para la preparación de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1)
CR20220153A (es) Derivados de 2–azaespiro [3.4] octano como agonistas de m4